Lactoferrin retargets adenoviruses to TLR4 to induce an abortive NLRP3-associated pyroptotic response in human dendritic cells

Short title: *TLR4-mediated HAdV-lactoferrin uptake in DCs*

Coraline Chéneau^{1†}, Karsten Eichholz^{1†‡}, Tuan Hiep Tran^{1†§}, Thi Thu Phuong Tran¹, Océane Paris¹, Corinne Henriquet², Martine Pugniere² & Eric J Kremer^{1*}

¹Institut de Génétique Moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France

²Institut de Recherche en Cancérologie de Montpellier, INSERM, Université Montpellier, Institut Régional du Cancer, Montpellier, France

† **Equal contribution**

‡ **Current address:** Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;

§ **Current address:** Faculty of Pharmacy, PHENIKAA University, Yen Nghia, Ha Dong, Hanoi 12116, Vietnam, PHENIKAA Research and Technology Institute (PRATI), A&A Green Phoenix Group JSC, No.167 Hoang Ngan, Trung Hoa, Cau Giay, Hanoi 11313, Vietnam

***Correspondence:** eric.kremer@igmm.cnrs.fr

Abstract

Despite decades of investigations, we still poorly grasp the immunogenicity of human adenovirus (HAdV)-based vaccines in humans. In this study, we explored the role of lactoferrin, which belong to the alarmin subset of antimicrobial peptides that provide immediate direct and indirect activity against a range of pathogens following a breach in tissue homeostasis. Lactoferrin is a globular, iron-sequestering, glycoprotein that can increase HAdV infection and maturation of antigen-presenting cells. However, the mechanism by which HAdV-lactoferrin complexes induce maturation is unknown. We show that lactoferrin redirects HAdVs from species B, C, and D to toll-like receptor 4 (TLR4) complexes on human mononuclear phagocyte. TLR4-mediated internalization induces an abortive NLRP3-associated pyroptotic response inducing pro-inflammatory cytokine release and disrupting plasma membrane integrity without cell death. These data impact our understanding of the immunogenicity of HAdV-based vaccines and may provide ways to increase their efficacy.

Introduction

The gaps in our understanding of the immunogenicity versus efficacy of viral vector-based vaccines are notable. For example, how does the rapid recruitment of immune cells and release of danger-associated molecular patterns (DAMPs) following vector delivery influence vaccine efficacy? In this study, we addressed the impact of a host defense peptide/protein (HDP) on human adenovirus (HAdV)-based vaccines. HDPs, also known as antimicrobial peptides, are evolutionary conserved effector molecules of the innate immune system. HDPs can act directly via antibiotic-like properties against a broad array of infectious agents [1,2], or indirectly by promoting the activation and/or maturation of antigen-presenting cells. Many HDPs are produced by neutrophils and epithelial cells of skin, oral mucosa, and the gastrointestinal tract. The cytoplasmic content of neutrophils, which are among the first leukocytes to infiltrate pathogen-infected and vaccine-injected tissues, is ~20% HDPs [3]. The rapid delivery of HDPs acts as part of the first line responders to the disruption of tissue homeostasis [4]. Functionally, HDPs are able to neutralize endotoxin, recruit and modulate the activities of immune cells, and induce angiogenesis. The alarmins (e.g. lactoferrin, α -defensin, and cathelicidin LL-37) are a subset of HDPs that also modulate innate and adaptive immune responses by directly engaging several pathways including pattern recognition receptor (PRR) signaling in antigen-presenting cells (APCs) [1,2]. Lactoferrin is an 80 kDa, multifunctional member of the transferrin family that sequesters iron, is produced largely by neutrophils, and its physiological concentration can reach mg/ml in some cases. Functionally, lactoferrin can induce dendritic cell (DC) maturation and, in the context of infections, drive Th1-cell responses [5–7].

In addition to their ability to influence innate and adaptive immune responses to bacteria, fungi, and enveloped viruses, some alarmins also influence adenovirus (AdV) uptake [8–10]. AdVs are 150 megaDaltons, ~90 nm diameter, nonenveloped proteinaceous particles containing a linear double-stranded DNA genome of ~36,000 ($\pm$ 9,000) bp. Human AdVs (HAdVs) are classified into species (A-G) and types (~80) based on serology and phylogeny. In most cases, HAdVs cause self-limiting respiratory, ocular and gastro-intestinal tract infections in all populations regardless of health standards. Over the last 40 years the vectorization and immunogenicity of HAdVs have been of increasing interest in the context of vaccines, gene transfer, and morbidity associated with HAdV reactivation in immune-compromised individuals. In epithelial cells, alarmins influence HAdV infections via multiple

mechanisms. Lactoferrin acts as a bridging factor during species C HAdV (types 1, 2, 5 and 6) infection in epithelial-like cells, independent of coxsackievirus adenovirus receptor (CAR), the primary cell surface attachment molecule for species C HAdVs [11]. Adams et al. reported that lactoferrin also mediates a modest increase in HAdV type 5 (HAdV-C5) uptake by human DC [9] and increased maturation. However, a mechanistic understanding of how increased uptake occurs and how DC maturation is induced, including which PRRs are engaged, are indispensable.

In this study, we characterize the mechanism by which HAdV-lactoferrin complexes induce human DC infection, inflammatory response, and maturation. We show that lactoferrin directly binds HAdV-C5, -D26, and -B35 with affinities in the micromolar range and increases HAdV uptake by mononuclear phagocytes. We demonstrate that lactoferrin re-targets HAdVs to toll-like receptor 4 (TLR4) complexes on the cell surface. Engagement of TLR4 complexes increases HAdV uptake, even in the presence of anti-HAdV neutralizing antibodies, and induces a cathepsin B-associated NLRP3 inflammasome, which includes caspase-1 activity, and release of interleukin 1 beta (IL-1 β) - but not cell death. This pathway appears to be a variation of the alternative NLRP3 pathway induced by LPS via TLR4 engagement. In addition to a better understanding of the immunogenicity of HAdVs and HAdV-based vectors and vaccines, our data resolve the discordance between the TLR4-associated response to HAdVs in mice versus that of human phagocytes [12,13].

Materials and Methods

Cells and culture conditions

Blood samples were obtained from >100 anonymous donors at the regional blood bank (EFS, Montpellier, France). An internal review board approved the use of human blood samples. Monocyte-derived dendritic cells (DCs) were generated from freshly isolated or frozen CD14⁺ monocytes using CD14 MicroBeads human (MiltenyiBiotec) in the presence of 50 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) and of 20 ng/ml interleukin-4 (IL-4) (PeproTech). DCs stimulation was performed 6 days post-isolation of monocytes. Monocyte-derived Langerhans cells (LCs) were generated using 200 ng/ml GM-CSF and 10 ng/ml TGF- β . 911 cells and 293 E4-pIX cells were grown in Dulbecco's modified Eagle medium (DMEM) and minimum essential medium (MEM α) with Earle's salts, L-glutamine supplemented with 10% fetal bovine serum (FBS).

Adenoviruses

The HAdV used in this study are replication-defective (deleted in the E1 region). The HAdV-C5 vector contained a GFP expression cassette. The HAdV-D26 vector contained a GFP-luciferase fusion expression cassette [14]. The HAdV-B35 vector contained a YFP expression cassette [15]. The vectors were propagated in 911 or 293 E4-pIX cells and purified to > 99% homogeneity by two CsCl density gradients.

DC stimulation with HAdV-lactoferrin complexes

DCs (4×10^5 in 400 μ l of complete medium) were incubated with HAdV-C5, HAdV-D26 or HAdV-B35 (0.1 to 2×10^4 physical particles (pp)/cell). We generated HAdV-lactoferrin complexes by incubating the virus with 40 μ g lactoferrin (Sigma-Aldrich) for 30 min at room temperature. This corresponds to 100 μ g/ml (1.25 μ M) lactoferrin in 400 μ l. These concentrations are similar to that found in an inflammatory environment of infected tissues. When specified, cells were complexed with IVIg (human IgG pooled from between 5,000 and 50,000 donors/batch) (Baxter SAS) or with lactoferricin (fragment of 49AA). Cells were incubated with HAdV-lactoferrin for 4 h, then washed and let incubated again for 24 h. The TLR4 agonist lipopolysaccharide (LPS) (Sigma-Aldrich) and NLRP3 inflammasome inducer nigericin (InvivoGen) were used at 100 ng/ml and 10 μ M, respectively, to induce NLRP3 inflammasome formation. The inhibitors were used at the following concentrations, TLR4 inhibitors TAK-242 (Merck Millipore) at 1 μ g/ml, oxPAPC (InvivoGen) at 30 μ g/ml, TRIF inhibitory peptide (InvivoGen) at 25 μ M, Syk inhibitor R406 (InvivoGen) at 5 μ M, KCl (Sigma-Aldrich) at 45 mM, ROS inhibitor N-acetyl-L-cysteine (Sigma-Aldrich) at 2 mM, cathepsin B inhibitor MDL 28170 (Tocris Bioscience) at 0.1 μ M, NLRP3 inhibitor MCC-950/CP-456773 (Sigma-Aldrich) at 10 μ M, Bay11-7082 (Sigma-Aldrich) at 10 μ M, caspase-1 inhibitor WEHD (Santa Cruz) and YVAD (InvivoGen) at 20 μ M, VX765 (InvivoGen) at 10 μ M, caspase-8 inhibitor Z-IEDT at 20 μ M, RIPK1 inhibitor GSK963 (Sigma-Aldrich) at 3 μ M, RIPK3 inhibitors GSK872 (Merck Millipore) at 3 μ M and necrosulfonamide (R&D systems) at 1 μ M. TLR4/MD-2, TLR4 (R&D Systems), MD-2 (PeproTech) recombinant protein and CD14 antibody (Beckman) were used at 20 μ g/ml. Inhibitors were added on cells and recombinant proteins or antibody were added on HAdV-lactoferrin complex 1 h before stimulation. TLR4 surface expression level was assess with an anti-TLR4 antibody (Miltenyi Biotech) after 4 or 24 h.

SPR analyses

Surface plasmon resonance (SPR) analyses were carried out on a BIAcore 3000 apparatus in HBS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) polysorbate 20, pH 7.4). HAdV-C5, HAdV-D26 and HAdV-B35 diluted in acetate buffer at pH 4 were immobilized on three different flow cells of a CM5 sensor chip by amine coupling according to the manufacturer instructions. Immobilization levels were between 3,500 and 4,000 RU. Flow cell 1, without immobilized HAdV, was used as a control. Lactoferrin was injected at 100 nM on the four flow cells simultaneously. For K_D determination different concentrations of lactoferrin (6.25 - 200 nM) were injected at 30 μ l/min during 180 s of association and 600 s of dissociation with running buffer. Regeneration was performed with pulses of gly-HCl pH 1.7. The kinetic constants were evaluated from the sensorgrams after double-blank subtraction with BIAevaluation software 3.2 (GE Healthcare) using a bivalent fitting model for lactoferrin. All experiments were repeated at least twice for each virus on a freshly coated flow cell.

Flow cytometry

Cellular GFP or YFP expression from the HAdV-C5, -B35, -D26 vectors was assayed by flow cytometry. Fluorescence intensity was assessed after complex treatment for 24 h. Cell membrane integrity was assessed by collecting cells by centrifugation 800 x g, the cell pellets were re-suspended in PBS, 10% FBS, 7-aminoactinomycin D (7-AAD) (Becton-Dickinson Pharmigen) and analyzed on a FACS Canto II (Becton-Dickinson Pharmigen) or NovoCyte (ACEA Biosciences) flow cytometer.

Inflammasome formation was monitored as previously described [16] with minor modifications. DCs (1.5×10^5 in 150 μ l of complete medium) were seeded in a conical bottom 96 well plate and incubated with HDP-HAdV complexes containing 20,000 HAdV pp/cell. LPS/nigericin and immune complexed HAdV-C5 (IC-HAdV) were used as positive controls to identify inflammasome positive cells. IC-HAdV-C5 were prepared with IVIg (human IgG pooled from between 1,000 and 50,000 donors/batch) (Baxter SAS) as previously described [17]. Cells were fixed by adding 50 μ l 4% PFA, PBS for 10 min on ice and centrifuged at 650 x g for 5 min. Supernatants were discarded and cells were permeabilized with 150 μ l PBS/3% FCS/0.1% saponin for 20 min and collected by centrifugation. Supernatant was removed, and cells were re-suspended in 100 μ l 1:500 rabbit anti-ASC (N-15)-R (Santa Cruz, sc-22514-R) PBS/3%FCS/0.1% saponin and incubated overnight at 4°C. Following overnight incubation, cells were pelleted at 650 x g for 5 min, washed once with 150 μ l PBS/3% FCS:0.1% saponin,

pelleted again and incubated for 45 min in 100 μ l 1:500 Alexa-488 1:500 donkey anti-rabbit PBS:3% FCS:0.1% saponin for 45 min at room temperature. Cells were collected again by centrifugation and re-suspended in 150 μ l PBS/ 3% FCS/0.1% saponin. The BD FACS-Canto II was used for acquisition. Samples were gated on DC and any doublets were excluded using forward light scattering (FSC)-area versus FSC width. Inflammasome positive cells were identified in the green channel as FL1-width low, and FL1-height high.

Cytokines secretion

Supernatants were collected after 4 or 24 h and the levels of TNF and IL-1 β were quantified by ELISA using OptEIA human TNF ELISA Set (BD Biosciences) and human IL-1 β /IL-1F2 DuoSet ELISA (R&D systems) following the manufacturer's instructions. In addition, 22 cytokines were detected by Luminex on Bio-plex Magpix using Bio-plex human chemokine, cytokine kit (Bio-Rad) following the manufacturer's instructions.

LDH release

LDH release was quantified using an LDH Cytotoxicity Assay Kit (Thermo scientific) following the manufacturer's instructions. Briefly, 5 x 10⁵ cells were cultures in 96-well plates, infected for 4 h, and 100 μ l of supernatant were collected to assess LDH activity. Fresh reaction mixture (100 μ l) was then added to each well, incubated at room temperature for 30 min, the reaction was stopped, and the absorbance was determined at 490 nm using a microplate reader (NanoQuant, Tecan).

Quantification of mRNAs

The levels of human *TNF*, *NLRP3*, *CASP1* and *IL1B* mRNAs were analyzed using quantitative reverse transcription-PCR (qRT-PCR). Total RNAs were isolated from DCs using a High Pure RNA isolation kit (Roche). Reverse transcription was performed with a Superscript III first-strand synthesis system (Invitrogen, Life Technologies) using 300 ng of total RNA and random hexamers. The cDNA samples were diluted 1:10 in water and analyzed in triplicate using a LightCycler 480 detection system (Roche, Meylan, France). PCR conditions were 95°C for 5 min and 45 cycles of 95°C for 15 s, 65°C or 70°C for 15 s, and 72°C for 15 s, targeting the *GAPDH* (glyceraldehyde-3-phosphate dehydrogenase) mRNA as an internal standard. Primer sequences were as follows for *NLRP3* (5'-CCTCTC TGATGAGGCCCAAG-3' (*NLRP3* forward) and 5'-GCAGCAAAGTGGAAAGGAAG-3' (*NLRP3* reverse)) at 65°C, *IL1B* (5'-AAACAGATGAAGTGCTCCTTCC-3' (*IL1B* forward) and 5'-

188 AAGATGAAGGGAAAGAAGGTGC-3' (*IL1B* reverse) at 65°C, *GAPDH* (5'-
 189 ACAGTCCATGCCATCACTGCC-3' (*GAPDH* forward) and 5'-
 190 GCCTGCTTCACCACCTTCTTG-3' (*GAPDH* reverse) at 70°C. Relative gene expression
 191 levels of each respective gene were calculated using the threshold cycle ($2^{-\Delta\Delta CT}$) method and
 192 normalized to *GAPDH* [17].

193 **Results**

194 **Lactoferrin binds to HAdV-C5, -D26 and -B35 and increases infection of DCs**

195 At physiological pH, HAdV-C5, -D26 and -B35 have patches of negative surface charges on
 196 hexon that should potentiate cationic alarmin binding. We therefore quantified the affinity of
 197 human lactoferrin to each virus capsid by surface plasmon resonance (SPR). The HAdVs were
 198 immobilized on a CM5 sensor chip and then escalating doses of lactoferrin were injected over
 199 the sensor surfaces. We found that lactoferrin binds the three HAdVs with affinities (K_D) that
 200 varied from 0.8 to 54 μ M (**Figure 1A & B, and Supplemental Figure 1A**).

201 In human myeloid and epithelial cells, HAdV-C5, HAdV-D26, and HAdV-B35 receptor use
 202 does not overlap [18]: HAdV-C5 predominantly uses CAR as an attachment molecules ,
 203 HAdV-D26 uses sialic acid-bearing glycans as a primary cell entry receptor [19], and HAdV-
 204 B35 predominantly uses CD46 [20]. We therefore tested the impact of lactoferrin on HAdV
 205 infection using replication-defective HAdV vector-mediated transgene expression, which is a
 206 surrogate assay for receptor engagement, internalization, cytoplasmic transport, docking at the
 207 nuclear pore, delivery of the genome to the nucleus, and transcription of the GFP expression
 208 cassette. Consistent with earlier reports [21], we found that lactoferrin increased (~2 to 4 fold)
 209 infection of human DCs by a species C HAdV (type 5), and in addition we show that HAdV-
 210 D26- and HAdV-B35-lactoferrin complexes are more infectious than the HAdV alone (**Figure**
 211 **1C & D**). Preincubating HAdVs with lactoferrin, adding lactoferrin to the cell medium before
 212 HAdV, or adding lactoferrin to the cell medium after HAdV, all increased HAdV infection
 213 efficacy (**Supplemental Figure 1B**). In addition, we found that lactoferrin-enhanced infection
 214 was not unique to DCs: -monocytes and monocyte-derived Langerhans cells were also more
 215 readily infected by HAdV-lactoferrin complexes (except HAdV-B35 on monocytes)
 216 (**Supplemental Figure 1C-D**). Together, these data demonstrate that at physiological
 217 concentrations lactoferrin binds to three HAdV types from different species and increased
 218 uptake by DC.

219 **HAdV-lactoferrin complexes induce DC cytokine secretion**

220 By influencing pathogen uptake alarmins could allow a host to better detect and respond to
 221 pathogens. Conversely, pathogen - alarmins interactions could reduce an APC's ability to
 222 present antigens and therefore dampen a downstream response. If the response were pro-host,

one would expect DC maturation and an inflammatory response. To determine whether HAdV-lactoferrin complexes influences DC maturation, we characterized the cytokine and chemokine profile using a multiplex array. Compared to mock-treated DCs, HAdV-D26 and HAdV-B35 induced a greater cytokine response than HAdV-C5 (**Figure 2A left column**). By contrast, compared to lactoferrin-treated DCs, HAdV-lactoferrin complexes induced an increase in the release of IL-1 α and IL-1 β (**Figure 2A center column**). When comparing HAdVs vs HAdV-lactoferrin complexes, the addition of lactoferrin induced a greater effect on HAdV-C5, which is likely due in part to the lower effect of HAdV-C5 alone (**Figure 2A right column, see Supplemental Figure 2A for raw data**). We then quantified IL-1 β in the supernatant in time-dependent assays from multiple donors. HAdV-lactoferrin complexes rapidly induced >100-fold more IL-1 β release than HAdVs alone, which further increased from 4 to 24 h post-stimulation (**Figure 2B**). In addition, monocytes also released more IL-1 β when challenged with HAdV-lactoferrin complexes compared to HAdV alone (**Supplemental Figure 2B**).

We previously showed that individual serum and pooled IgGs (IVIG) containing anti-HAdV-C5 neutralizing IgGs induced the maturation of human DCs [17,22]. To benchmark the effects induced by lactoferrin, we compared HAdVs complexed with IVIG, lactoferrin or IVIG/lactoferrin. We found that HAdV-lactoferrin complexes led to a greater efficacy of gene transfer (higher percentage of cells expressing GFP). HAdVs complexed with IVIG/lactoferrin also led to more GFP/infected cell (more GFP^{high} cell) than HAdV-IVIG complexes (**Figure 2C and Supplemental Figure 2C**). Moreover, more IL-1 β was released when IVIG and lactoferrin were combined with the HAdVs, consistent with observation that IL-1 β release is directly linked to HAdV infection (**Figure 2D**). In addition, HAdV-lactoferrin complexes decreased phagocytosis, a hallmark of functional DC maturation (**Supplemental Figure 2D**). Together, these data demonstrate that lactoferrin-associated HAdV infection is associated with DC cytokine secretion and functional maturation.

TLR4 is involved HAdV-lactoferrin induced DC maturation

Increased infection could be due to a handful factors, including alternative receptor engagement and/or more efficient intracellular trafficking. Of note, lactoferrin may increase DC maturation and IL-1 β release by interacting with TLR4 [5,23–25]. In some myeloid cells TLR4 forms a complex with MD-2 for ligand binding [26] and with CD14 for TLR4

internalization [27]. MD-2 acts as a co-receptor for recognition of both exogenous ligands and endogenous ligands [26,28,29]. In addition, Doronin *et al.* proposed that HAdVs, via a murine coagulation FX-bridge, interact with murine TLR4 [12]. Yet, human FX did not act as a bridge for HAdV-C5 via TLR4 on human DCs [13]. We therefore probed the possible interactions between HAdV-lactoferrin complexes and the TLR4 pathway. To determine whether HAdV-lactoferrin complexes engage the TLR4 complex on the cell surface, we incubated the complexes with recombinant TLR4, MD-2, or TLR4/MD-2 dimers, or blocked CD14 on the cell surface with an anti-CD14 antibody. We found the greatest reduction of infection in the presence of the TLR4/MD-2 dimer (**Figure 3A and Supplemental Figure 3A**). To address the involvement of the cytoplasmic TLR4 domain, we used TAK-242, a cell-permeable cyclohexene-carboxylate to disrupt TLR4 interaction with adaptor molecules TIRAP and TRAM [30–32]. We found that TAK-242 reduced HAdV-lactoferrin-mediated infection, IL-1 β release and TNF secretion in DCs (**Figure 3B-C**). By contrast, interruption of TLR4-TIRAP/TRAM interactions had no notable impact on the infection of DCs, monocytes, or Langerhans cells by the HAdVs alone (**Supplemental Figure 3B - D**). We then used oxPAPC and TRIF inhibitory peptide (Pepinh-TRIF) to inhibit extracellular TLR4 - MD2 interactions and cytoplasmic TLR4 - TRIF interactions, respectively. oxPAPC and Pepinh-TRIF decreased infection of HAdV-C5- and HAdV-D26-lactoferrin, while infection by HAdV-B35-lactoferrin increased (**Figure 3D-E**).

We then perturbed TLR4-MyD88-Syk activation of the NF- κ B pathway using R406 and Bay11-7082. R406 decreased HAdV-lactoferrin infections, consistent with its impact on TLR4-MyD88-Syk associated endocytosis, while Bay11-7082 had no effect on infection, consistent with its downstream signaling role (**Figure 3E**). Importantly, all of the drugs and peptides affecting TLR4 interactions reduced IL-1 β release (**Figure 3F**). In addition, lactoferrin, TAK-242, and Pepinh-TRIF did not change TLR4 surface expression, while high concentration of oxPAPC increased TLR4 levels (**Supplemental Figure 3E-G**).

Of note, lactoferrin is also posttranslationally cleaved to generate lactoferricin, a biologically active N-terminal fragment of 49 aa. Lactoferricin also binds to negatively charged hexon hypervariable regions (HVRs) of HAdV-C5, -A31 and -B35 [33]. To determine if lactoferricin could mimic the effects of lactoferrin, we incubated the former with the HAdV vectors. We found no notable increase in HAdV infections or IL-1 β release (**Supplemental Figure 3H & I**, respectively), suggesting that the C-terminal fragment plays a role in HAdV-TLR4

interactions. Together, these data demonstrate that interfering with TLR4 engagement/signaling reduces HAdV-lactoferrin-mediated transgene expression and DCs maturation in the case of HAdV-C5 and -D26.

HAdV-lactoferrin complexes induce NLRP3 inflammasome formation

The inflammasome is a multiprotein cytosolic platform consisting of a PRR that induces nucleation of ASC (apoptosis associated speck-like protein containing a CARD), and recruitment of pro-caspase 1. Pro-caspase-1 auto-activation can be followed by removal of the N-terminal of gasdermin D (GSDMD), which initiates the loss of plasma membrane integrity via pore formation [34]. Classic NLRP3 inflammasome formation (canonical and non-canonical) is preceded by transcriptional priming event (signal 1) needed to produce inflammasome components and cytokines [35]. TLR4 engagement by LPS induces an alternative NLRP3 inflammasome activation, which does not need transcriptional priming, in human mononuclear phagocytes [36]. To determine whether HAdV-lactoferrin complexes induced transcription of inflammasome components, we used RT-qPCR to examine the mRNAs of inflammasome components. We found that in most cases HAdV-lactoferrin complexes significantly increased *NLRP3*, *CASP1*, *IL1B* and *TNF* mRNAs compared to the HAdVs (alone) (**Figure 4A**). To directly address inflammasome formation, we used flow cytometry to detect inflammasome-containing DCs using aggregation of ASC as a readout. During inflammasome formation, ASC changes from being distributed throughout the cytoplasm to an aggregate of ~1 μ m diameter upon nucleation by a NLRP3. ASC nucleation can be directly visualized by changes in the fluorescence pulse width/ratio. While this assay does not allow quantification of all the cells that contain, or will contain an inflammasome, it does provide a snapshot of inflammasome formation at a given time. We found that <1% of mock-treated DCs contained an inflammasome. LPS/nigericin and HAdV-C5 complexed with neutralizing IgGs in IVIG (HAdV-C5-IgG) [17] had ~5 and 4% inflammasome-positive cells, respectively (~40% of the DCs will undergo pyroptosis in 8 h when incubated with this concentration of HAdV-C5-IgG [17]). We found an increase in the number of inflammasome-positive DCs 3 h post-challenge with HAdV-C5-lactoferrin complexes (**Figure 4B**). While the number of inflammasome containing cells were similar following challenges with HAdV-B35-lactoferrin complex compare to HAdV-C5- and HAdV-D26-lactoferrin, the difference was modest compared to HAdV-B35 alone.

317 As IL-1 β release is associated with both classic and alternative activation of NLRP3
318 inflammasomes, we explored the initiation steps. Inducers of NLRP3 inflammasome include
319 K⁺ efflux, Ca²⁺ signaling, mitochondrial dysfunction, lysosomal rupture, or PRR engagement
320 [34]. To identify the HAdV-lactoferrin-associated trigger(s), DCs were treated with KCl (to
321 prevent K⁺ efflux), NAC (reactive oxygen species scavenger), and MDL (cathepsin B
322 inhibitor). The addition of extracellular K⁺, and NAC did not decrease the release of IL-1 β
323 (**Figure 4C**). By contrast, MDL significantly reduced IL-1 β release (**Figure 4C**), suggesting
324 that rupture of lysosome-related organelles was involved. To determine whether the IL-1 β
325 release is linked to an NLRP3 inflammasome, DCs were pre-incubated with MCC-950
326 (NLRP3 inhibitor), which attenuated IL-1 β release in response to HAdV-lactoferrin
327 complexes (**Figure 4D**).

328 We then examined the role of the caspases by incubating cells with Z-WEHD-FMK (caspase-
329 1, -4, -5 and -8 inhibitor), Z-YVAD-FMK (caspase-1, -4 and -5 inhibitor), VX765 (caspase-1
330 and -4 inhibitor) or Z-IETD (caspase-8 inhibitor). Globally, all inhibitors that affected
331 caspase-1 and -8 activity reduced IL-1 β release (**Figure 4E-G**). In addition to the direct effects
332 of TLR4 engagement and signaling, it was possible that TNF secretion induced an autocrine
333 response and inflammasome activation via the RIPK1-RIPK3-caspase-8 pathway [37]. While
334 inhibition of the TNFR pathway (using GSK963, necrosulfonamide, and GSK872) had no
335 significant effect on infection (**Figure 4H**), IL-1 β release was reduced in all cases. Possibly
336 because HAdV-B35-lactoferrin complexes typically induced greater levels of IL-1 β release,
337 the effects of the caspase inhibitors tended to be more prominent (**Supplemental Figure 4A-C**
338 for effect of inhibitors for each HAdV). Together, these data demonstrate that HAdV-
339 lactoferrin complexes induce NLRP3 inflammasome formation and IL-1 β release via a
340 cathepsin B-mediated activation of caspase 1. Additionally, an autocrine effect of TNF may
341 influence IL-1 β release.

342 **IL-1 β release without the loss of membrane integrity**

343 In contrast to classic NLRP3 inflammasome activation, the alternative pathway does not
344 include complete loss of cell membrane integrity (as based on LDH release into the
345 extracellular space). This is thought to be due to ESCRT III pathway repairing pores in the
346 plasma membrane induced by limited levels of GSDMD cleavage [38]. To determine if
347 HAdV-lactoferrin complexes induce pores and the release of large intracellular proteins, we

348 quantified extracellular levels of L-lactate dehydrogenase (LDH) activity at 4 h postinfection.
 349 LDH activity in the supernatant of control and HAdV-lactoferrin complexes was not
 350 significantly different from HAdV or lactoferrin-treated controls (**Figure 5A**). To determine
 351 whether HAdV-lactoferrin complexes were able to have a long-term impact DC membrane
 352 integrity we add a fluorescent marker of viability (7-AAD) to the DCs and quantified 7-AAD⁺
 353 cells by flow cytometry. At 24 h post-challenge, the percentage of 7-AAD⁺ cell induced by
 354 HAdV-lactoferrin complexes was greater than lactoferrin- or HAdV-challenged cells (**Figure**
 355 **5B**). Moreover, when lactoferrin was added to HAdV–IVIG complexes, we found an increase
 356 in the percentage of 7-AAD⁺ DCs (**Supplemental Figure 5**). These data demonstrate that
 357 membrane integrity may be perturbed, but within the time frame of our assays cytosolic
 358 proteins are not releases into the medium. Together, these data demonstrated that HAdV-
 359 lactoferrin complexes prime DCs for NLRP3-associated IL-1 β release, inflammasome can be
 360 formed, membrane integrity is perturbed, but there is no significant leakage of cytoplasmic
 361 proteins.

Discussion

Deconstructionist approaches using binary systems to understand HAdV receptor engagement, trafficking, and immunogenicity provided a foundation to understand virus - cell interactions. Combinatorial assays using multiple human blood components can generate greater insight into clinically relevant HAdV issues, in particular tropism and immunogenicity. Here, we show how an alarmin influences the response of human DCs to three HAdV types. We examined pathways from receptor engagement, signaling, transcription, inflammasome formation/activation and cytokine release (**Figure 6**). Following engagement of TLR4, its TIR domain recruits MyD88 and TIRAP, which bridge TLRs to IRAK and MAPK family members that activate NF- κ B, AP-1, and IRF. This latter pathway initiates transcription of genes coding for inflammasome components and proinflammatory cytokines [39,40]. The TIR domain also recruits TRAM and TRIF to activate the kinases TBK1 and IKK ϵ to promote type I IFN expression [30]. Together, these innate immune pathways prime an adaptive antiviral response.

Due in part to the technical advances in the synthesis of peptide-polymer conjugates, interest in new and old HDPs is flourishing. However, the complex biological functions of naturally occurring HDPs provide a candid reminder of how little we grasp their impact on immune responses to most pathogens. The three HAdV types used in this study were based on their state of development as vectors for vaccines [41,42]. HAdV-C5, -D26 and -B35 come from different HAdV species, and are associated with different vaccines efficacy. The *raison d'être* for the use of HAdV-D26 and -B35 is that their low seroprevalence (at least in Europeans and North Americans cohorts) and may circumvent some concerns associated with pre-existing HAdV humoral immunity [43]. It is worth noting that HAdV-B35 seroprevalence is typically rare – whether this is due to the lack of infection or lack of production of neutralizing antibodies to HAdV-B35 is currently unknown. Throughout this study HAdV-C5 and -D26 tended to have similar profiles in all assays. By contrast, there were several instances where HAdV-B35 was notably different. Whether these differences can be attributed to the use of CD46 or differences in the level between monocytes, DCs or Langerhans is possible, but unexplored. In addition, work in T cells that shows CD46 primes the NLRP3 inflammasome and therefore a possible binary engagement through TLR4 and CD46 could impact the response to HAdV-B35-lactoferrin complexes [44]. The breadth of the lactoferrin-enhanced infection of the three HAdVs suggest that the interactions are charge based because of the

394 significant differences in the HVR sequences, which make up much of the surface area of
 395 HAdVs. Previous studies demonstrated that some HDPs attenuate HAdV infection of
 396 epithelial-like cells [8,15,45–48]. By contrast, our results are similar to Adams et al. [9] and
 397 demonstrated that lactoferrin-enhanced HAdV infection of human monocytes, DCs, and
 398 Langerhans cells. By delving deeper into these initial observations, our study sheds light onto
 399 the mechanisms by which an HDP connects HAdV infection of mucosal tissues, or during
 400 vaccination, to drive innate and adaptive immune responses. Mechanistically, it appears that
 401 lactoferrin reduces infection of epithelial cells and increases uptake into phagocytes, which
 402 provokes a pro-inflammatory and antiviral cytokine response. In combination with vaccination
 403 studies in paradigms of primary and recurrent infection, our study will help us understand how
 404 this pathway modifies adaptive immune responses against HAdV vectors and/or the transgene.

405 Classical NLRP3 inflammasome activation involves a two-step process: PRR-derived signal 1
 406 to upregulate transcription of inflammasome components and NLRP3 posttranslational
 407 modification. NLRP3 then detects perturbations of cellular integrity associated with K⁺ efflux
 408 (signal 2). Consequently, Nek7–NLRP3 interaction leads to pyroptosome assembly and
 409 caspase-1-induced maturation of pro-IL-1 β and pro-GSDMD. The alternative pathway
 410 consists of NLRP3-ASC-pro-caspase-1 signaling and IL-1 β release without the loss of
 411 cytoplasmic content via GSDMD-induced pyroptosis. Yet, the alternative pathway delineated
 412 in this study is not an indisputable fit and likely reflects the variability between LPS and a
 413 HAdV. TLR4-mediated endocytosis, which is well characterized for LPS, depends on the
 414 homodimerization of TLR4. LPS, the quintessential TLR4 ligand, is extracted from gram⁻
 415 bacteria by CD14, which then transfer it to MD-2, which interacts directly with TLR4. TLR4
 416 dimerization is induced by the Lipid A region of LPS. Given the icosahedral shape and the
 417 size (~90 nm) of the HAdV-lactoferrin complex, one would expect that lactoferrin binds to
 418 multiple sites on the capsid and induced TLR4 dimerization directly, or possibly assemblage
 419 of multiple dimers. Dimerization is then associated with a CD14-dependent migration [49] to
 420 cholesterol-rich regions of the plasma membrane and endocytosis via a TLR4 ectodomain-
 421 dependent mechanism. While this picture appears partially consistent with the uptake HAdV
 422 particles, CD14 levels on monocytes-derived DCs are very low or absent, suggesting that
 423 migration to lipid rafts is via another pathway. The involvement of cathepsin B, a product of
 424 lysosomal rupture, is a key result. Most TLR4 agonists examined to date do not have complex
 425 intracellular processing. This is not the case for HAdVs. The endosomolytic activity of protein

426 VI, an internal capsid protein, prevents the efficient degradation of the HAdVs in DCs by
 427 enabling the escape of HAdV capsid from endocytic vesicles/lysosomes into the cytoplasm
 428 [50,51]. However, this trafficking process causes the HAdV double-stranded DNA genome
 429 become accessible to AIM2 (absent in melanoma 2) and in turn the initiation of an
 430 inflammasome. The makeup and processing of TLR4-associated vs. Fc γ receptor-associated
 431 endocytic vesicles is, to the best of our knowledge, unknown. From the data here, it appears
 432 that TLR4-associated endocytic vesicles fused to the cathepsin B-bearing lysosomal vesicles
 433 before the rupture of these vesicles causes the inception of an NLRP3 inflammasome. Of note,
 434 we did not detect an involvement of the cGAS pathway (the inhibitor RU.512 had no effect on
 435 HAdV-mediated transgene expression or IL-1 β release, data not shown) suggesting that in our
 436 assays TLR4-mediated endocytosis was not associated with significant degradation of the
 437 HAdV capsid. These data are consistent with increased GFP expression. By inhibiting caspase
 438 1, we showed that it is activated and involved in IL-1 β release. This effect was specific for IL-
 439 1 β , as TNF secretion did not decrease (**Supplemental Figure 6A**). Furthermore, caspase
 440 inhibitors had no effect on HAdV-lactoferrin entry (**Supplemental Figure 6B**). Caspase 1
 441 cleavage of GSDMD abolishes its intra-molecular auto-inhibition and induces pore-like
 442 structures of ~15 nm in diameter in the plasma membrane to breakdown the ion gradients.
 443 Alternative inflammasome activation can be triggered by a unique signal. LPS sensing induces
 444 a TLR4-TRIF-RIPK1-FADD-CASP8 signaling axis, resulting in activation of NLRP3 by
 445 cleavage of an unknown caspase-8 substrate independently of K⁺ efflux. The alternative
 446 NLRP3 complex likely has a modified stoichiometry. Although caspase 1 becomes mature and
 447 cleaves IL-1 β , pyroptosis is not induced and IL-1 β release by an unconventional mechanism
 448 that functions independently of GSDMD. Why the inflammasome in HAdV-lactoferrin
 449 challenged cells does not lead to GSDMD-mediated release of cytoplasmic content may be
 450 due to the spatial and temporal signals the cell is receiving during the activation phase. In
 451 classic NLRP3 inflammasome activation, signal 1 is received well before signal 2 (NLRP3
 452 engagement). In our assays, HAdV-lactoferrin induced signals are received immediately
 453 before the NLRP3 induction. Notably though, inhibition of the NF- κ B pathway had a dramatic
 454 effect on IL-1 β levels. The lack of coordination of transcriptional priming and de-
 455 ubiquitination of NLRP3 [52] may preclude pyroptosis, and favor an immune response with a
 456 longer duration and trafficking of DC to lymph node to induce an adaptive immune responses.
 457 Inflammasome activation is thought to be crucial for the induction of cellular and humoral
 458 immune responses in the context of vaccinations. However, whether the involvement of the

HAdV-lactoferrin NLRP3 axis drives T-cell responses towards a Th1 or Th2 phenotype needs further analyses. By contrast, controlling excessive inflammatory response is necessary. In addition to the expression of IL-1 β , we also found notable levels of IL-1 α . It is also possible that the effects of IL-1 α supersede or preclude pyroptosis because IL-1 α can promote the expression of genes involved in cell survival [53].

Of note, our results may also resolve one of many conundrums associated with the differences between murine and human responses to HAdVs. If murine HDPs interact with murine coagulation factors to bind HAdVs and induce a TLR4-associated pro-inflammatory response in the mouse liver [12], then the addition of ubiquitous HDPs into this picture could resolve the paradox. Whether HAdV-coagulation factor- HDP-HAdV complexes are produced following intravenous injection in mice has not been addressed. In conclusion, using combinatorial assays and primary human blood cells we detailed the multifaceted interactions between a PAMP (HAdV), a DAMP (lactoferrin), and PRRs (TLR4 & NLRP3) at the interface of innate and adaptive immunity in humans. These data directly address how the multiple layers of the innate and adaptive immune responses coordinate reactions to pathogens.

Acknowledgments

We thank the imaging facility MRI, member of the national infrastructure France-BioImaging supported by the French National Research Agency (ANR-10-INBS-04, “Investments for the future”). We thank Katryn Stacey (CHU Montpellier) for help with the inflammasome detection by flow cytometry. We thank EKL members for constructive comments.

Author contributions:

Study design & conception: KE, EJK
Project direction: EJK
Performed experiments: CC, KE, HT, TTPT, OP, CH
Analyzed data: all authors
Wrote the manuscript: CC, KE, HT & EJK
Secured funding: EJK

Data and materials availability: All materials can be obtained through an MTA.

References

1. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30: 131–141. doi:10.1016/j.it.2008.12.003

- 491 2. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and
492 their modes of action. *Trends Biotechnol.* Elsevier Ltd; 2011;29: 464–472.
493 doi:10.1016/j.tibtech.2011.05.001
- 494 3. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, et al. Vaccine
495 adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that
496 participate in antigen transport to draining lymph nodes. *Vaccine.* 2011;29: 1812–1823.
497 doi:10.1016/j.vaccine.2010.12.090
- 498 4. da Cunha NB, Cobacho NB, Viana JFC, Lima LA, Sampaio KBO, Dohms SSM, et al. The next
499 generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of
500 diseases with social and economic impacts. *Drug Discov Today.* 2017;22: 234–248.
501 doi:10.1016/j.drudis.2016.10.017
- 502 5. Spadaro M, Montone M, Arigoni M, Cantarella D, Forni G, Pericle F, et al. Recombinant
503 human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2
504 and 4. *FASEB J.* 2014;28: 416–429. doi:10.1096/fj.13-229591
- 505 6. Spadaro M, Caorsi C, Ceruti P, Varadhachary A, Forni G, Pericle F, et al. Lactoferrin , a major
506 defense protein of innate immunity , is a novel maturation factor for human dendritic cells.
507 2016;22: 2747–2757. doi:10.1096/fj.07-098038
- 508 7. de la Rosa G, Yang D, Tewary P, Varadhachary A, Oppenheim JJ. Lactoferrin acts as an
509 alarmin to promote the recruitment and activation of APCs and antigen-specific immune
510 responses. *J Immunol.* 2008;180: 6868–6876. doi:10.4049/jimmunol.180.10.6868
- 511 8. Smith JG, Silvestry M, Lindert S, Lu W, Nemerow GR, Stewart PL. Insight into the
512 mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. *PLoS*
513 *Pathog.* 2010;6: e1000959.
- 514 9. Adams WC, Bond E, Havenga MJE, Holterman L, Goudsmit J, Karlsson Hedestam GB, et al.
515 Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-
516 independent receptor pathway mediated by lactoferrin and DC-SIGN. *J Gen Virol.* 2009;90:
517 1600–1610. doi:10.1099/vir.0.008342-0
- 518 10. Uchio E, Inoue H, Kadonosono K. Anti-adenoviral effects of human cationic antimicrobial
519 protein-18/LL-37, an antimicrobial peptide, by quantitative polymerase chain reaction. *Korean J*
520 *Ophthalmol.* 2013;27: 199–203. doi:10.3341/kjo.2013.27.3.199
- 521 11. Johansson C, Jonsson M, Marttila M, Persson D, Fan XL, Skog J, et al. Adenoviruses use
522 lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells. *J Virol.*
523 2007;81: 954–963.
- 524 12. Doronin K, Flatt JW, Di Paolo NC, Khare R, Kalyuzhniy O, Acchione M, et al. Coagulation
525 factor X activates innate immunity to human species C adenovirus. *Science* (80). 2012;338:
526 795–798. doi:10.1126/science.1226625
- 527 13. Eichholz K, Mennechet FJD, Kremer EJ. Coagulation factor X-adenovirus type 5 complexes
528 poorly stimulate an innate immune response in human mononuclear phagocytes. *J Virol.*
529 2015;89: 2884–2891. doi:10.1128/JVI.03576-14
- 530 14. Weaver EA, Barry MA. Low seroprevalent species D adenovirus vectors as influenza vaccines.
531 *PLoS One.* 2013;8: 1–14. doi:10.1371/journal.pone.0073313
- 532 15. Smith JG, Nemerow GR. Mechanism of adenovirus neutralization by Human alpha-defensins.
533 *Cell Host Microbe.* 2008/01/15. 2008;3: 11–19. doi:S1931-3128(07)00308-3
534 doi:10.1016/j.chom.2007.12.001
- 535 16. Sester DP, Thygesen SJ, Sagulenko V, Vajjhala PR, Cridland JA, Vitak N, et al. A novel flow
536 cytometric method to assess a novel flow cytometric method to assess inflammasome
537 formation. *J Immunol.* 2015;194: 455–462. doi:10.4049/jimmunol.1401110

- 538 17. Eichholz K, Bru T, Tran TTP, Fernandes P, Welles H, Mennechet FJD, et al. Immune-
539 complexed adenovirus induce AIM2-mediated pyroptosis in human dendritic cells. *PLoS*
540 *Pathog.* 2016;12. doi:10.1371/journal.ppat.1005871
- 541 18. Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. *Rev Med*
542 *Virol.* 2009;19: 165–178.
- 543 19. Baker AT, Mundy RM, Davies JA, Rizkallah PJ, Parker AL. Human adenovirus type 26 uses
544 sialic acid-bearing glycans as a primary cell entry receptor. *Sci Adv.* 2019;5: 2–11.
545 doi:10.1126/sciadv.aax3567
- 546 20. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses.
547 *Nat Med.* 2003;9: 1408–1412.
- 548 21. Günther PS, Mikeler E, Hamprecht K, Schneider-Schaulies J, Jahn G, Dennehy KM.
549 CD209/DC-SIGN mediates efficient infection of monocyte-derived dendritic cells by clinical
550 adenovirus 2C isolates in the presence of bovine lactoferrin. *J Gen Virol.* 2011;92: 1754–1759.
551 doi:10.1099/vir.0.030965-0
- 552 22. Tran TTP, Eichholz K, Amelio P, Moyer C, Nemerow GR, Perreau M, et al. Humoral immune
553 response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of
554 regulatory T cells. *PLoS Pathog.* 2018;14: 1–31. doi:10.1371/journal.ppat.1007127
- 555 23. Ando K, Hasegawa K, Shindo KI, Furusawa T, Fujino T, Kikugawa K, et al. Human lactoferrin
556 activates NF- κ B through the Toll-like receptor 4 pathway while it interferes with the
557 lipopolysaccharide-stimulated TLR4 signaling. *FEBS J.* 2010;277: 2051–2066.
558 doi:10.1111/j.1742-4658.2010.07620.x
- 559 24. Nagaoka I, Hirota S, Niyonsaba F, Hirata M, Adachi Y, Tamura H, et al. Cathelicidin Family of
560 Antibacterial Peptides CAP18 and CAP11 Inhibit the Expression of TNF- by Blocking the
561 Binding of LPS to CD14+ Cells. *J Immunol.* 2001;167: 3329–3338.
562 doi:10.4049/jimmunol.167.6.3329
- 563 25. Scott MG, Vreugdenhil ACE, Buurman WA, Hancock REW, Gold MR. Cationic Antimicrobial
564 Peptides Block the Binding of Lipopolysaccharide (LPS) to LPS Binding Protein. *J Immunol.*
565 2000;164: 549–553. doi:10.4049/jimmunol.164.2.549
- 566 26. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, et al. MD-2, a Molecule that
567 Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4. *J Exp Med.* 1999;189:
568 1777–1782. doi:10.1084/jem.189.11.1777
- 569 27. Zanoni I, Ostuni R, Marek LR, Barresi S, Barbalat R, Barton GM, et al. CD14 controls the
570 LPS-induced endocytosis of Toll-like receptor 4. *Cell.* Elsevier Inc.; 2011;147: 868–880.
571 doi:10.1016/j.cell.2011.09.051
- 572 28. Rallabhandi P, Phillips RL, Marina S. Respiratory Syncytial Virus Fusion Protein-Induced Toll-
573 Like Receptor 4 (TLR4) Signaling Is Inhibited by the TLR4 Antagonists Rhodobacter
574 sphaeroides Lipopolysaccharide and Eritoran (E5564) and Requires Direct Interaction with
575 MD-2. *MBio.* 2012;3: e00218--12. doi:10.1128/mBio.00218-12.Editor
- 576 29. Deguchi A, Tomita T, Omori T, Komatsu A, Ohto U, Takahashi S, et al. Serum amyloid A3
577 binds MD-2 to activate p38 and NF- κ B pathways in a MyD88-dependent manner. *J Immunol.*
578 2013;191: 1856–1864. doi:10.4049/jimmunol.1201996
- 579 30. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, et al. TRAM is specifically
580 involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. *Nat*
581 *Immunol.* 2003;4: 1144–1150. doi:10.1038/ni986
- 582 31. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, et al. LPS-TLR4
583 Signaling to IRF-3/7 and NF- κ B Involves the Toll Adapters TRAM and TRIF. *J Exp Med.*
584 2003;198: 1043–1055. doi:10.1084/jem.20031023

- 585 32. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-
586 like receptor 4 to the induction of interferon- β . *Nat Immunol.* 2008;9: 361–368.
587 doi:10.1038/ni1569
- 588 33. Persson BD, Lenman A, Frängsmyr L, Schmidt M, Ahlm C, Plückthun A, et al. Lactoferrin-
589 hexon interactions mediate CAR-independent adenovirus infection of human respiratory cells. *J*
590 *Viol.* 2020;(in press). doi:10.1128/JVI.00542-20
- 591 34. He Y, Hara H, Núñez G. Mechanism and Regulation of NLRP3 Inflammasome Activation.
592 *Trends Biochem Sci.* 2016;41: 1012–1021. doi:10.1016/j.tibs.2016.09.002
- 593 35. Gaidt MM, Hornung V. Alternative inflammasome activation enables IL-1 β release from living
594 cells. *Curr Opin Immunol.* 2017;44: 7–13. doi:10.1016/j.coi.2016.10.007
- 595 36. Gaidt MM, Ebert TS, Chauhan D, Schmidt T, Schmid-Burgk JL, Rapino F, et al. Human
596 Monocytes Engage an Alternative Inflammasome Pathway. *Immunity.* 2016;44: 833–846.
597 doi:10.1016/j.immuni.2016.01.012
- 598 37. Najjar M, Saleh D, Zelic M, Nogusa S, Shah S, Tai A, et al. RIPK1 and RIPK3 Kinases
599 Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4. *Immunity.* 2016;45:
600 46–59. doi:10.1016/j.immuni.2016.06.007
- 601 38. Rühl S, Shkarina K, Demarco B, Heilig R, Santos JC, Broz P. ESCRT-dependent membrane
602 repair negatively regulates pyroptosis downstream of GSDMD activation. *Science (80-).*
603 2018;362: 956–960. doi:10.1126/science.aar7607
- 604 39. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides
605 signalling specificity for Toll-like receptors. *Nature.* *Nature;* 2002;420: 329–333.
606 doi:10.1038/nature01180
- 607 40. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, et al. Essential role for
608 TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. *Nature.* 2002;420:
609 324–9. doi:10.1038/nature01182
- 610 41. Ertl HC. Viral vectors as vaccine carriers. *Curr Opin Virol.* 2016;21: 1–8.
611 doi:10.1016/j.coviro.2016.06.001
- 612 42. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, et al. International
613 epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36
614 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine
615 trials. *Vaccine.* 2010;28: 950–957. doi:10.1016/j.vaccine.2009.10.145
- 616 43. Mennechet FJDD, Paris O, Ouoba AR, Salazar Arenas S, Sirima SB, Takoudjou Dzomo GR, et
617 al. A review of 65 years of human adenovirus seroprevalence. *Expert Rev Vaccines.* 2019;18:
618 597–613. doi:10.1080/14760584.2019.1588113
- 619 44. Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C, et al. T helper 1
620 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. *Science*
621 *(80-).* 2016;352: aad1210–aad1210. doi:10.1126/science.aad1210
- 622 45. Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro.
623 *Regul Pept.* 2001;101: 157–161.
- 624 46. Pietrantoni A, Maria A, Biase D, Tinari A, Marchetti M, Valenti P, et al. Bovine Lactoferrin
625 Inhibits Adenovirus Infection by Interacting with Viral Structural Polypeptides Bovine
626 Lactoferrin Inhibits Adenovirus Infection by Interacting with Viral Structural Polypeptides.
627 2003; doi:10.1128/AAC.47.8.2688
- 628 47. Arnold D, Di Biase AM, Marchetti M, Pietrantoni A, Valenti P, Seganti L, et al. Antiadenovirus
629 activity of milk proteins: Lactoferrin prevents viral infection. *Antiviral Res.* 2002;53: 153–158.
630 doi:10.1016/S0166-3542(01)00197-8

- 631 48. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. Human
632 cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has
633 potent antibacterial and antiviral activity. *Curr Eye Res.* 2005;30: 385–394.
634 doi:10.1080/02713680590934111
- 635 49. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. Mediators of innate immune
636 recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell
637 activation. *J Cell Sci.* 2002;115: 2603–2611.
- 638 50. Wiethoff CM, Nemerow GR. Adenovirus membrane penetration: Tickling the tail of a sleeping
639 dragon. *Virology.* 2015;479–480: 591–599. doi:10.1016/j.virol.2015.03.006
- 640 51. Moyer CL, Nemerow GR. Disulfide-bond formation by a single cysteine mutation in
641 adenovirus protein VI impairs capsid release and membrane lysis. *Virology.* 2012;428: 41–47.
642 doi:10.1016/j.virol.2012.03.024
- 643 52. Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3
644 Critically Regulates Inflammasome Activity. *Mol Cell.* 2013;49: 331–338.
645 doi:10.1016/j.molcel.2012.11.009
- 646 53. Netea MG, van de Veerdonk FL, van der Meer JWM, Dinarello CA, Joosten LAB.
647 Inflammasome-Independent Regulation of IL-1-Family Cytokines. *Annu Rev Immunol.*
648 2015;33: 49–77. doi:10.1146/annurev-immunol-032414-112306
- 649

Figure Legends

Figure 1. Lactoferrin binds to HAdVs and increase infectivity in DCs

- A) Representative sensorgrams of lactoferrin binding to the HAdV capsid as assessed by surface plasmon resonance. HAdV-C5 (red), HAdV-D26 (black), and HAdV-B35 (blue) were covalently coupled to a CM5 sensor chip and lactoferrin was injected for binding comparison. For K_D determination a range of 6.25 - 200 nM of lactoferrin was injected and the K_D was calculated using a bivalent fitting model (RU = resonance units);
- B) Relative affinity (K_D) of lactoferrin for HAdV-C5, -D26 and -B35 capsids;
- C) Representative flow cytometry profiles of DCs incubated with the HAdV vectors. DCs were mock-treated (grey) or incubated with HAdV species-C5 (5,000 pp/cell), -D26 (20,000 pp/cell) or -B35 (1,000 pp/cell) (red) or complexed with lactoferrin (blue) for 24 h. Samples were collected at 24 h, prepared for flow cytometry and 25,000 events were acquired/sample.
- D) Cumulative data (n = 21) from DCs generated from blood bank donors.

Figure 2. HAdV-lactoferrin complexes induce IL-1 α and IL-1 β

- A) DCs were incubated with HAdV-C5, HAdV-D26, and HAdV-B35 $\pm$ lactoferrin (or LPS as a positive control) for 4 h and cytokines secretion in supernatants was assessed by Luminex. To the left of each set of columns is the baseline reference set: for the left-hand columns the baseline is mock-infected cells, for the middle columns the reference is lactoferrin-treated cells, for the right-hand columns the reference is HAdV-infected cells. Raw data can be found in (Supplemental Figure 2A & B).
- B) IL-1 β release by DCs in the presence of HAdV-C5, -D26, and -B35 $\pm$ lactoferrin was assessed by ELISA at 4 (red) and 24 h (black) postinfection (n = 3). As control, cells were treated with LPS (TLR4 agonist) and nigericin (activated the inflammasome).
- C-D) DCs were incubated with HAdV complexed with lactoferrin, IVIG or lactoferrin + IVIG, for 4 h. Infection and IL-1 β release, respectively, were analyzed 24 h postinfection (n = 3). Statistical analyses by two-tailed Mann-Whitney test.

Figure 3. Blocking TLR4 engagement and signaling decrease HAdV-lactoferrin entry and DC maturation

- A) HAdV-lactoferrin complexes were incubate with TLR4/MD-2 recombinant protein for 30 min. Infection was analyzed 24 h postinfection by flow cytometry (n = 11);
- B) DCs were treated for 1 h pre-infection with TAK-242, HAdV-lactoferrin complex infection was analyzed 24 h postinfection by flow cytometry (n $\geq$ 3). Cytokine profile of DCs treated HAdV-lactoferrin $\pm$ TAK-242;
- C) IL-1 β release following inhibition with TAK-242;
- D) TNF levels 24 h postinfection $\pm$ TAK-242 (n $\geq$ 3);
- E) Percent infection following inhibition with oxPAPC (n = 6);
- F) Percent infection following inhibition with Pepinh-TRIF, R406 or Bay11-7082 (n = 6).
- G) IL-1 β release from DCs incubated with HAdV-lactoferrin $\pm$ oxPAPC, Pepinh-TRIF, R406 or Bay11-7082 (n $\geq$ 3). Statistical analyses by two-tailed Mann-Whitney test.

Figure 4. HAdV-lactoferrin complexes induce IL-1 β via an NLRP3 inflammasome

- A) mRNA expression of inflammasome components NLRP3 (NLRP3), caspase 1 (CASP1), pro-IL-1 β (IL1B) and TNF (TNF) induced by HAdV-lactoferrin complex was assessed by RT-qPCR at 4 h postinfection;
- B) Flow cytometry-based assay for ASC aggregation (pyroptosome formation); Inflammasome formation was induced by incubating DCs with HAdV-C5- lactoferrin complexes for 3 h. LPS +

nigericin and HAdV-C5-IVIG complexes were used as positive controls to identify inflammasome-positive cells. MCC-950 was used as a control of NLRP3 inhibition and lactoferrin on DCs was used as a negative control. Cells were stained with anti-ASC. Inflammasome-positive cells were identified as ASC-width low and ASC-height high.

C) IL-1 β release in response to HAdV-lactoferrin complex or LPS/nigericin in DCs pre-treated with NLRP3 pathway or caspase-1 inhibitor. IL-1 β release in response to HAdV-lactoferrin complexes in DCs pre-treated with C) KCl, NAC, and MDL; D) NLRP3 inhibitor MCC-950; E-F) caspase-1 inhibitors WEDH, YVAD, VX765; G) caspase-8 inhibitor Z-IETD, H) RIPK1 inhibitor GSK963, and RIPK3 inhibitors necrosulfonamide and GSK872. $N \geq 3$ in all assays. Statistical analyses by two-tailed Mann-Whitney test.

Figure 5. IL-1 β release without the loss of membrane integrity

- A) DCs were challenged with HAdV-lactoferrin complexes, HAdV alone, or LPS/nigericin. Loss of cytosolic content was quantified by LDH activity in the supernatant at 4 h postinfection ($n = 6$);
- B) Plasma membrane integrity, analyzed 24 h postinfection using 7-AAD uptake, was quantified using flow cytometry ($n = 13$). Statistical analyses by two-tailed Mann-Whitney test.

Figure 6. TLR4-mediated HAdV-lactoferrin uptake in DCs and IL-1 β release

Lactoferrin binds to HAdV capsid and retargets the virus toward TLR4 complex on the cells surface. Following TLR4 engagement, its TIR domain recruits MyD88 and TIRAP, which bridge TLRs to IRAK and MAPK family members that activate NF- κ B, AP-1, and IRF. This is a transcriptional priming event that initiating expression of genes coding for inflammasome components (e.g. NLRP3 and IL-1 β). The DC then detects a second perturbations (signal 2) which induced ROS release (mitochondrial stress) or K⁺ efflux (perturbations of cellular integrity), and cathepsin B release from lysosome rupture. HAdV-lactoferrin complexes induce RIPK1/3 pathway through autocrine-TNF release or RIPK3 activation via TRIF. During inflammasome formation, pro-caspase-1 auto-activation induces cleavage of pro-IL-1 β and likely GSDMD, which will initiate the loss of plasma membrane integrity via pore formation, allowing IL-1 β release. Twenty-four hours post-challenge, DCs membrane integrity is intact, consistent with the involvement of ESCRT-III complex and repairing GSDMD pores.

Supplementary Materials

Figure S1: Analysis of lactoferrin binding to HAdV-C5, -D26 and -B35 by SPR

A) HAdV-C5, HAdV-D26, and HAdV-B35 were covalently couple to a CM5 sensor chip and escalating doses of lactoferrin (6.25-200 nM) for K_D determination. Depicted are overlaid sensorgrams (RU = resonance units);

B) Representative flow cytometry profiles of cells infected with HAdV vectors. DCs were mock-treated (grey), incubated with HAdV species -C5, -D26 and -B35 alone (red), with lactoferrin complexed with HAdV (blue), with HAdV for 30 min and then lactoferrin (green) or with lactoferrin for 30 min and then HAdV (purple). Fluorescence was analyzed 24 h postinfection;

C) monocytes and **D)** LCs were incubated with HAdVs $\pm$ lactoferrin and fluorescence was analyzed 24 h postinfection (n = 3).

Figure S2: HAdV-lactoferrin complexes induce cytokine secretion

A) Raw data of Luminex assay of DCs $\pm$ HAdVs $\pm$ lactoferrin, plus controls.

B-C) Freshly isolate human monocytes incubated with HAdV-C5-, HAdV-D26, and HAdV-B35 $\pm$ lactoferrin. The supernatants were used to quantify IL-1 β release, GFP expression is reported median fluorescent index (MFI), respectively (n = 3)

D) DCs were incubate with HAdV-lactoferrin complexes for 24 h. Cells were then incubated at 4°C or 37°C for 30 min with 1 mg/ml Texas Red-labelled dextran, washed with PBS, and immediately analyzed by flow cytometry to determine DC functional maturation (lower fluorescence = lower phagocytosis = greater maturation, n = 2).

Figure S3: TLR4 inhibitors reduce infection of HAdV-lactoferrin complexes

A) HAdV-lactoferrin complexes were incubate with TLR4, TLR4/MD-2, MD-2 recombinant proteins or DCs were incubated with anti-CD14 antibody for 30 min. Then HAdV-lactoferrin-recombinant protein complexes were added to DCs or HAdV-lactoferrin were added to treated DCs. Infection was analyzed 24 h postinfection by flow cytometry (n = 4).

B-D) DCs, monocytes, or LCs were treated for 1 h pre-infection with 1 μ g/ml of TAK-242. HAdV-lactoferrin complex infection was analyzed 24 h postinfection by flow cytometry (n = 3).

TLR4 surface expression was analyzed at 24 h after DCs treatment with decrease concentrations of **E)** lactoferrin (7 - 0.9 μ g/ml), **F)** TAK-242 (200 - 25 μ g/ml), **G)** oxPAPC (60 - 7.5 μ g/ml) or Pepinh-TRIF (50 - 6.25 μ g/ml) (n $\geq$ 3).

HAdV were complexed with lactoferrin or with lactoferricin (a gift from H. Jenssen, Roskilde Universitet).

H-I) DC infection and IL-1 β release were analyzed at 24 h postinfection, respectively (n = 4). Statistical analyses by two-tailed Mann-Whitney test.

Figure S4: Pharmacological inhibition organized by HAdV type

DCs were treated for 1 h pre-infection with TLR4 inhibitors oxPAPC, Pepinh-TRIF, Syk inhibitor R406, NLRP3 inhibitor Bay11-7082, RIPK1 inhibitor GSK963 and RIPK3 inhibitors necrosulfonamide and GSK872 (n $\geq$ 3). Cells were infected with **A)** HAdV-C5-lactoferrin, **B)** HAdV-D26-lactoferrin or **C)** HAdV-B35-lactoferrin complexes and IL-1 β release was analyzed 24 h postinfection (n $\geq$ 3). Statistical analyses by two-tailed Mann-Whitney test.

Figure S5: Lactoferrin combined with IVIG induced 7-AAD uptake

DCs were incubated with HAdV complexed with lactoferrin, IVIG or lactoferrin + IVIG. Plasma membrane integrity was analyzed by 7-AAD uptake by flow cytometry at 24 h postinfection (n = 3). Statistical analyses by two-tailed Mann-Whitney test.

767 **Figure S6: Caspase-1 and -8 inhibitors do not impact TNF secretion or infection**

768 DCs were treated with caspase-1 inhibitors (YVAD or VX765) or caspase-8 inhibitor (Z-IETD) for 1 h.

769 Cells were infected with HAdV-lactoferrin complexes for 24 h.

770 **A-B)** Supernatant was collected for TNF quantification; and, **C)** cells for GFP expression (flow

771 cytometry) ($n \geq 4$). Statistical analyses by two-tailed Mann-Whitney test.

FIGURE 1

A

B

Virus	K_D (nM)
HAdV-C5	800
HAdV-D26	2550
HAdV-B35	54000

C

D

Fig 1

FIGURE 2

Fig 2

FIGURE 4

Fig 4

FIGURE S1

Fig S1

FIGURE S2

Fig S2

FIGURE S3

Fig S3

FIGURE S4

Fig S4

FIGURE 5

A

B

Fig 5

FIGURE S5

Fig S5

FIGURE S6

Fig S6

FIGURE 6

Fig 6